TY - JOUR
T1 - Colonic drug delivery
T2 - Formulating the next generation of colon-targeted therapeutics
AU - McCoubrey, Laura E.
AU - Favaron, Alessia
AU - Awad, Atheer
AU - Orlu, Mine
AU - Gaisford, Simon
AU - Basit, Abdul W.
N1 - Funding Information:
This project has received funding from the Engineering and Physical Sciences Research Council (EPSRC) UK, grant number EP/S023054/1 to the UCL School of Pharmacy. Support was also partially obtained from the Interreg 2 Seas programme 2014-2020 co-funded by the European Regional Development Fund under subsidy contract “Site Drug 2S07-033” and the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 956851.
Funding Information:
This project has received funding from the Engineering and Physical Sciences Research Council (EPSRC) UK, grant number EP/S023054/1 to the UCL School of Pharmacy . Support was also partially obtained from the Interreg 2 Seas programme 2014-2020 co-funded by the European Regional Development Fund under subsidy contract “Site Drug 2S07-033” and the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 956851.
Publisher Copyright:
© 2022 The Authors
Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.
PY - 2023/1/31
Y1 - 2023/1/31
N2 - Colonic drug delivery can facilitate access to unique therapeutic targets and has the potential to enhance drug bioavailability whilst reducing off-target effects. Delivering drugs to the colon requires considered formulation development, as both oral and rectal dosage forms can encounter challenges if the colon's distinct physiological environment is not appreciated. As the therapeutic opportunities surrounding colonic drug delivery multiply, the success of novel pharmaceuticals lies in their design. This review provides a modern insight into the key parameters determining the effective design and development of colon-targeted medicines. Influential physiological features governing the release, dissolution, stability, and absorption of drugs in the colon are first discussed, followed by an overview of the most reliable colon-targeted formulation strategies. Finally, the most appropriate in vitro, in vivo, and in silico preclinical investigations are presented, with the goal of inspiring strategic development of new colon-targeted therapeutics.
AB - Colonic drug delivery can facilitate access to unique therapeutic targets and has the potential to enhance drug bioavailability whilst reducing off-target effects. Delivering drugs to the colon requires considered formulation development, as both oral and rectal dosage forms can encounter challenges if the colon's distinct physiological environment is not appreciated. As the therapeutic opportunities surrounding colonic drug delivery multiply, the success of novel pharmaceuticals lies in their design. This review provides a modern insight into the key parameters determining the effective design and development of colon-targeted medicines. Influential physiological features governing the release, dissolution, stability, and absorption of drugs in the colon are first discussed, followed by an overview of the most reliable colon-targeted formulation strategies. Finally, the most appropriate in vitro, in vivo, and in silico preclinical investigations are presented, with the goal of inspiring strategic development of new colon-targeted therapeutics.
KW - Artificial intelligence and machine learning
KW - Drug delivery systems and the large intestine
KW - Gastrointestinal microbiota and microbiome
KW - Inflammatory bowel disease and drug products
KW - Oral biologics and biopharmaceuticals
KW - Targeting the colon
KW - Administration, Oral
KW - Biological Availability
KW - Pharmaceutical Preparations
KW - Colon
KW - Drug Delivery Systems
UR - http://www.scopus.com/inward/record.url?scp=85144615909&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2022.12.029
DO - 10.1016/j.jconrel.2022.12.029
M3 - Review article
C2 - 36528195
AN - SCOPUS:85144615909
VL - 353
SP - 1107
EP - 1126
JO - Journal of Controlled Release
JF - Journal of Controlled Release
SN - 0168-3659
ER -